<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hwang, Hyung Bin</style></author><author><style face="normal" font="default" size="100%">Lee, Wook-Bin</style></author><author><style face="normal" font="default" size="100%">Kim, Kyung-A</style></author><author><style face="normal" font="default" size="100%">Ahn, Hong Ryul</style></author><author><style face="normal" font="default" size="100%">Kang, Tae Kyeom</style></author><author><style face="normal" font="default" size="100%">Lee, Jong Jin</style></author><author><style face="normal" font="default" size="100%">Kim, Min Kyoung</style></author><author><style face="normal" font="default" size="100%">Kang, Kui Dong</style></author><author><style face="normal" font="default" size="100%">Jung, Sang Hoon</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Preventive Effect of &lt;em&gt;Diospyros kaki&lt;/em&gt; on Intraocular Pressure and Dry Eye: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial</style></title><secondary-title><style face="normal" font="default" size="100%">medRxiv</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2025-01-01 00:00:00</style></date></pub-dates></dates><elocation-id><style  face="normal" font="default" size="100%">2025.07.21.25331959</style></elocation-id><doi><style  face="normal" font="default" size="100%">10.1101/2025.07.21.25331959</style></doi><volume><style face="normal" font="default" size="100%"></style></volume><issue><style face="normal" font="default" size="100%"></style></issue><abstract><style  face="normal" font="default" size="100%">Background Dry eye disease (DED) is a common chronic ocular disorder associated with ocular discomfort and tear film damage. Traditional medicinal uses of Diospyros kaki leaves have been well-documented for their potent radical-scavenging, antioxidant, and immune-modulatory properties. Emerging evidence suggests that D. kaki leaves can improve various ocular conditions, including dry eye disease and elevated intraocular pressure (IOP), making it a potential therapeutic option for managing these conditions.Methods A randomized controlled trial was conducted involving one hundred patients diagnosed with mild DED. The participants were divided into placebo and treatment groups, receiving maltodextrin and EEDK (600 mg/day). Clinical efficacy, clinical indices, and adverse reactions were compared between the two groups.Results Administration of EEDK significantly improved tear film stability and corneal staining scores in patients with DED. IOP significantly decreased after EEDK administration. The EEDK group exhibited significant improvements in tear film stability compared with the placebo group at 4, 8, and 12 weeks. Consistent reductions in IOP and corneal staining scores were observed throughout the 12-week study period in the EEDK group. Moreover, EEDK intake effectively enhanced tear production as evidenced by the Schirmer test. No significant adverse events were observed.Conclusions The oral administration of EEDK demonstrated significant therapeutic effects in improving dry eye symptoms without notable adverse events. The results of this study suggest that EEDK could be considered an ideal therapeutic option for treating patients with dry eye disease.Trial registration The trial is registered with the Korean Clinical Trial Registry, KCT0010532Highlights- Ethanol extract of Diospyros kaki (EEDK) improves dry eye symptoms and tear film stability.- EEDK significantly reduces intraocular pressure in patients with dry eye disease.- Randomized, double-blind, placebo-controlled clinical trial conducted over 12 weeks.- No significant adverse events observed, indicating EEDK is well-tolerated.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialKCT0010532Funding StatementThis work was supported by an intramural grant (2E33531) from the Korea Institute of Science and Technology (KIST), Republic of Korea. Funding is also provided by Whanin Pharm Co., Ltd., Seoul, Korea.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was reviewed and approved by the Institutional Review Board (IRB) of The Catholic University of Korea.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript</style></abstract></record></records></xml>